首页> 外文学位 >Design, synthesis, biological testing and QSAR analysis of new Schiff bases of N-hydroxysemicarbazide as inhibitors of tumor cells.
【24h】

Design, synthesis, biological testing and QSAR analysis of new Schiff bases of N-hydroxysemicarbazide as inhibitors of tumor cells.

机译:N-羟基氨基脲的新型席夫碱作为肿瘤细胞抑制剂的设计,合成,生物学测试和QSAR分析。

获取原文
获取原文并翻译 | 示例

摘要

Ribonucleotide reductase (RR) is a rate-limiting enzyme involved in de novo DNA synthesis, and is considered to be a potential target for cancer chemotherapy. Among all RR inhibitors investigated, only hydroxyurea (HU) is currently used for the treatment of various cancers, but it has several drawbacks. To obtain more potent and selective RR inhibitors, thirty-one title compounds were synthesized. Their molecular structures and purity were established by NMR, IR and MS spectra, and by elemental analyses.;The cytotoxicities of the 31 compounds were first evaluated against murine leukemia L1210 cells using the MTS/PES colorimetric assay. Seventeen of the 31 compounds exhibited higher cytotoxicities than HU against the L1210 cells. Six compounds with IC50 values in the micromolar range (2.7--7.2 muM) were found to be 11 to 30-fold more potent than HU (IC50 = 82 muM).;The active compounds were further tested against human leukemia CCRF-CEM cells and four solid tumor cells. Among these, three new compounds (RWL-4, 21, 35) inhibited the CCRF-CEM cells with IC50 values ranging from 2.7 to 7.0 muM. RWL35 [1-(9-[10-methylanthryl]methylene)-4-hydroxysemicarbazide] was the strongest inhibitor, and showed 74 to 692-fold activity, compared to HU, against the solid tumor cells tested. RWL35 exhibited more favorable selectivity (8--187 fold) than HU, and had no cross-resistance with HU and gemcitabine, two known RR inhibitors.;The log P and pKa values of a model compound, RWL1 [1-(3-trifluoromethylbenzylidene)-4-hydroxysemicarbazide], were measured by the shake-flask method, and then the Hansch-Fujita pi constant of the functional group---CH=NNHONHOH was derived for the calculation of log P of other congeners. Besides the essential pharmacophore (-NHCONHOH), among the physicochemical parameters examined in the QSAR analysis, hydrophobicity (log P), molecular size/polarizability (MR) and the indicator variable (I) for o-oxygen function turned out to be the important determinants of the antitumor activities observed.;Six of the title compounds have been shown to be remarkable inhibitors of various tumor cells including the HU-resistant cells. The most active compounds merit additional investigations for further development as anticancer drugs.
机译:核糖核苷酸还原酶(RR)是涉及DNA从头合成的限速酶,被认为是癌症化疗的潜在靶标。在所研究的所有RR抑制剂中,目前仅使用羟基脲(HU)来治疗各种癌症,但它有几个缺点。为了获得更有效和选择性的RR抑制剂,合成了31种标题化合物。通过NMR,IR和MS光谱以及元素分析确定了它们的分子结构和纯度。首先使用MTS / PES比色测定法评估了31种化合物对鼠白血病L1210细胞的细胞毒性。在31种化合物中,有17种对L1210细胞的毒性高于HU。发现六种IC50值在微摩尔范围(2.7--7.2μM)的化合物比HU(IC50 = 82μM)的效力高11到30倍;进一步测试了这些活性化合物对人白血病CCRF-CEM细胞的作用和四个实体瘤细胞。其中,三种新化合物(RWL-4、21、35)抑制CCRF-CEM细胞,IC50值为2.7至7.0μM。 RWL35 [1-(9- [10-甲基蒽基]亚甲基] -4-羟基氨基脲]是最强的抑制剂,与HU相比,对所测试的实体瘤细胞显示74至692倍的活性。 RWL35具有比HU更好的选择性(8--187倍),并且与HU和吉西他滨(两种已知的RR抑制剂)没有交叉抗性。模型化合物RWL1的log P和pKa值[1-(3-用摇瓶法测定[三氟甲基亚苄基] -4-羟基氨基脲],然后推导官能团的Hansch-Fujita pi常数--CH = NNHONHOH,计算其他同类物的logP。除了基本药效团(-NHCONHOH)以外,在QSAR分析中检查的理化参数中,疏水性(log P),分子大小/极化率(MR)和邻氧功能的指示变量(I)被证明是重要的观察到的抗肿瘤活性的决定因素。六种标题化合物已显示是各种肿瘤细胞(包括HU耐药细胞)的显着抑制剂。最具活性的化合物值得进一步研究,以进一步发展为抗癌药。

著录项

  • 作者

    Ren, Shijun.;

  • 作者单位

    University of Southern California.;

  • 授予单位 University of Southern California.;
  • 学科 Chemistry Pharmaceutical.;Health Sciences Oncology.
  • 学位 Ph.D.
  • 年度 2001
  • 页码 297 p.
  • 总页数 297
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号